Amundi Sells 408,736 Shares of Johnson & Johnson $JNJ

Amundi lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 3.5% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 11,191,098 shares of the company’s stock after selling 408,736 shares during the period. Johnson & Johnson comprises 0.6% of Amundi’s holdings, making the stock its 21st biggest position. Amundi owned 0.46% of Johnson & Johnson worth $1,747,983,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. SCS Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 207.1% in the 2nd quarter. SCS Capital Management LLC now owns 171,664 shares of the company’s stock valued at $26,222,000 after acquiring an additional 115,759 shares during the last quarter. Marshall Wace LLP lifted its position in Johnson & Johnson by 73.5% during the second quarter. Marshall Wace LLP now owns 1,583,553 shares of the company’s stock valued at $241,888,000 after purchasing an additional 670,669 shares during the period. Portland Global Advisors LLC boosted its holdings in Johnson & Johnson by 2.1% in the second quarter. Portland Global Advisors LLC now owns 6,727 shares of the company’s stock valued at $1,028,000 after purchasing an additional 136 shares during the last quarter. Epoch Investment Partners Inc. grew its position in Johnson & Johnson by 4.6% during the 2nd quarter. Epoch Investment Partners Inc. now owns 493,373 shares of the company’s stock worth $75,363,000 after purchasing an additional 21,830 shares during the period. Finally, Royal Fund Management LLC raised its stake in shares of Johnson & Johnson by 11.1% during the 2nd quarter. Royal Fund Management LLC now owns 28,080 shares of the company’s stock valued at $4,292,000 after buying an additional 2,798 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of analyst reports. UBS Group raised their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research note on Tuesday, October 14th. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. The Goldman Sachs Group upped their price objective on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Citigroup raised their target price on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, October 15th. Finally, Raymond James Financial upped their price target on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $202.10.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $202.24 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $207.81. The stock has a market cap of $487.25 billion, a PE ratio of 19.52, a P/E/G ratio of 2.29 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a 50 day moving average price of $193.61 and a 200 day moving average price of $174.90.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion for the quarter. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.